ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年11月18日 15時00分
Source:
Eisai
エーザイ、社会的責任投資指数「Dow Jones Sustainability Asia Pacific Index」に7回目の選定
東京, 2020年11月18日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、社会的責任投資(Social Responsibility Investment: SRI)の世界的投資指数である「Dow Jones Sustainability Index」(DJSI)のアジア・太平洋版「DJSI Asia Pacific Index」の対象銘柄に選定されましたのでお知らせします。当社は今回が7回目の選定となります。
「DJSI」は、RobecoSAM AG(スイス)とS&P Dow Jones Indices LLC(米国)とが1999年に開発した指標であり、経済・環境・社会の3つの観点から企業の持続可能性を評価するものです。環境・社会・ガバナンス(ESG)を中心とする非財務価値向上に対する企業の取り組みを重視する世界中の投資家にとって、重要な投資判断基準の一つになっています。今回、アジア・太平洋地域の企業を対象にした「DJSI Asia Pacific Index」には、同地域の主要企業約600社から上位158社(うち日本企業は82社)が選定されました。当社は、「イノベーションマネジメント」「気候戦略」「環境報告」「人権」などの項目において高い評価を受けました。
当社は、「DJSI」と並ぶ世界的SRI株価指数である「FTSE4Good Index Series」や、年金積立金管理運用独立行政法人(GPIF)によって採用されている日本株の4つのESG投資指数である「MSCI 日本株女性活躍指数(WIN)」、「FTSE Blossom Japan Index」、「MSCIジャパンESGセレクト・リーダーズ指数」および「S&P/JPXカーボンエフィシエント指数」にも選定されています。
当社は、患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念と定めています。当社は、この理念の実現のために、ESGへの取り組みを強化し、非財務価値を高めることにより、持続的企業価値向上に努めてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202076.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 04, 2026 09:06 JST
DENSO Announces Third Quarter Financial Results
Feb 03, 2026 19:36 JST
Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations
Feb 03, 2026 11:14 JST
EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions
Feb 03, 2026 10:00 JST
SGL Golf Launches in U.S. Market to Meet Demand for Autonomous Course Management Solutions
Feb 03, 2026 03:00 JST
Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 02, 2026 16:29 JST
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 02, 2026 14:30 JST
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 02, 2026 10:00 JST
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST
ANIME TOKYO STATION ON ROBLOX: Commemorating the One-Year Anniversary with Gifts and a Wealth of Add-on Content
Jan 30, 2026 09:00 JST
MAZDA CX-5 Achieves Five Million Units in Global Production and Sales
Jan 29, 2026 16:15 JST
The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment
Jan 29, 2026 12:00 JST
Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
Jan 29, 2026 10:14 JST
TANAKA Recognized as a "Tokyo Sports Promotion Company" for the 11th Consecutive Year
Jan 28, 2026 22:00 JST
NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 2026
Jan 28, 2026 18:29 JST
MHI Thermal Systems Receives "Minister of Economy, Trade and Industry Award" and MHI's Aerospace Parts Factory Receives "Agency for Natural Resources and Energy Commissioner's Award" at 2025 Energy Conservation Grand Prize Awards
Jan 28, 2026 18:08 JST
Mitsubishi Power Completes GTCC Upgraded Reliability Package at VPI's Damhead Creek Power Station
Jan 28, 2026 17:58 JST
Fujitsu and Tokai National Higher Education and Research System develop space weather prediction capabilities technology leveraging AI
Jan 28, 2026 10:55 JST
NEC Develops High-Efficiency, Compact Power Amplifier Module for 5G Base Station Radio Units
Jan 28, 2026 10:05 JST
Shoucheng Holdings-Backed Robotics Firms Set to Appear at 2026 CMG New Year's Gala
Jan 28, 2026 09:35 JST
More Latest Release >>
Related Release
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/26/2026 11:37:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
1/21/2026 4:44:00 PM JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
12/3/2025 6:19:00 PM JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
12/3/2025 12:01:00 AM JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
11/28/2025 11:00:00 PM JST
More Press release >>